how many people use glp-1 drugs trends 2025: real-world data, patient outcomes & future therapies US households with GLP-1 users
Description
Wang CA, Lin LC, Chen JY, Wang WJ, Wu VC
doi: 10.1111/dom.13764
Chronic Disease Prevalence : Rising global rates of type 2 diabetes and obesity are expanding the patient pool for GLP1 therapies, increasing demand for both glycemic and weight management indications
The FDA approval of the first oral GLP-1 medication for obesity in December 2025 represents a major milestone in weight loss treatment options
Despite trying restrictive diets, intense exercise regimens, and costly supplements, the scale rarely moves in a meaningful or lasting way
